Ladenburg Thalmann Financial Services reiterated their buy rating on shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in a research report released on Wednesday morning. They currently have a $31.00 price objective on the stock, up from their prior price objective of $28.00.

AXSM has been the topic of several other research reports. Zacks Investment Research lowered Axsome Therapeutics from a buy rating to a hold rating in a research note on Friday, June 16th. Aegis reaffirmed a buy rating and set a $20.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, June 20th. BTIG Research assumed coverage on Axsome Therapeutics in a research note on Friday, May 19th. They set a buy rating and a $14.00 price target on the stock. Finally, ValuEngine raised Axsome Therapeutics from a strong sell rating to a sell rating in a research note on Wednesday, June 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $17.08.

Shares of Axsome Therapeutics (AXSM) opened at 6.15 on Wednesday. The company’s market capitalization is $145.17 million. The company’s 50 day moving average is $5.31 and its 200-day moving average is $4.58. Axsome Therapeutics has a 52 week low of $3.53 and a 52 week high of $9.11.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, May 9th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, analysts expect that Axsome Therapeutics will post ($1.43) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/axsome-therapeutics-inc-axsm-receives-buy-rating-from-ladenburg-thalmann-financial-services/1462822.html.

Several institutional investors have recently modified their holdings of AXSM. Goldman Sachs Group Inc. purchased a new position in shares of Axsome Therapeutics during the first quarter valued at about $121,000. SG Americas Securities LLC purchased a new position in shares of Axsome Therapeutics during the first quarter valued at about $139,000. Nexthera Capital LP purchased a new position in shares of Axsome Therapeutics during the first quarter valued at about $1,560,000. Sphera Funds Management LTD. purchased a new position in shares of Axsome Therapeutics during the first quarter valued at about $1,564,000. Finally, Royce & Associates LP purchased a new position in shares of Axsome Therapeutics during the first quarter valued at about $3,436,000. 32.93% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.